Chemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapy.

ABSTRACT: Oncolytic virotherapy has made significant progress in recent years, however, widespread approval of virotherapeutics is still limited. Primarily, this is due to the fact that currently available virotherapeutics are mostly tested in monotherapeutic clinical trials exclusively (ie, not in combination with other therapies) and so far have achieved only small and often clinically insignificant responses. Given that the predominantly immunotherapeutic mechanism of virotherapeutics is somewhat time-dependent and rapidly growing tumors therefore exhibit only minor chances of being captured in time, scenarios with combination partners are postulated to be more effective. Combinatory settings would help to achieve a rapid stabilization or even reduction of onset tumor masses while providing enoug

SUBMITTER: Binz E 

PROVIDER: S-EPMC4918378 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature